{"organizations": [], "uuid": "7f005e5a98d86523553ea49f0f4e93d3db4bf361", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-regneurosearch-and-teva-pharmaceut/brief-regneurosearch-and-teva-pharmaceutical-international-enter-into-agreement-on-outstanding-obligations-idUSFWN1SN0XK", "country": "US", "domain_rank": 408, "title": "BRIEF-RegNeurosearch And Teva Pharmaceutical International Enter Into Agreement On Outstanding Obligations", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-17T01:31:00.000+03:00", "replies_count": 0, "uuid": "7f005e5a98d86523553ea49f0f4e93d3db4bf361"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-regneurosearch-and-teva-pharmaceut/brief-regneurosearch-and-teva-pharmaceutical-international-enter-into-agreement-on-outstanding-obligations-idUSFWN1SN0XK", "ord_in_thread": 0, "title": "BRIEF-RegNeurosearch And Teva Pharmaceutical International Enter Into Agreement On Outstanding Obligations", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "neurosearch", "sentiment": "negative"}, {"name": "teva", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - Neurosearch A/S:\n* REG-NEUROSEARCH AND TEVA PHARMACEUTICAL INTERNATIONAL ENTER INTO AGREEMENT ON OUTSTANDING OBLIGATIONS\n* AGREEMENT TO RELEASE TEVA FROM OUTSTANDING OBLIGATIONS PURSUANT TO 2012 AGREEMENT CONCERNING TRANSFER OF CO’S RIGHTS IN AND TO PRIDOPIDINE\n* PROVIDED AGREEMENT IS COMPLETED,CO’S FINANCIAL EXPECTATIONS FOR 2018 WILL BE AMENDED FROM LOSS OF DKK 3.5-4.5 MILLION TO LOSS OF DKK 0.8-1.8 MILLION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-17T01:31:00.000+03:00", "crawled": "2018-05-17T14:36:39.018+03:00", "highlightTitle": ""}